Stocktoria
bioAffinity Technologies, Inc. BIAF
bioAffinity Technologies, Inc. (BIAF) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $6.2M at a -242.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BIAF | bioAffinity Technologies, Inc. | 3/9 | — | — | — |
| ABSI | Absci Corp | 2/9 | -1.9 | — | — |
| ISPC | iSpecimen Inc. | 3/9 | — | — | — |
| ONMD | OneMedNet Corp | 5/9 | — | — | — |
| VSBC | VITASPRING BIOMEDICAL CO. LTD. | 4/9 | — | — | — |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
FAQ
Is BIAF financially healthy?
bioAffinity Technologies, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does BIAF pay a dividend?
No, bioAffinity Technologies, Inc. does not currently pay a dividend.
How profitable is BIAF?
In FY2025, bioAffinity Technologies, Inc. had a net margin of -242.0% and a return on equity of -204.9%.
Is BIAF a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on bioAffinity Technologies, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.